Treximet - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:46Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Triptans]]
			[[Category:NSAIDs]]
			[[Category:Antimigraine agents]]
			[[Category:Fixed-dose combinations]]

MDElliottMD: home-claude house-rule fix (terminology, Mark ruling)

2026-05-23T04:53:16Z

home-claude house-rule fix (terminology, Mark ruling)

← Older revision		Revision as of 04:53, 23 May 2026
Line 7:		Line 7:
	\| starting_dose = 1 tablet (85/500 mg sumatriptan/naproxen) PO at migraine onset; may repeat after 2 hours if needed; maximum 2 tablets per 24 hours		\| starting_dose = 1 tablet (85/500 mg sumatriptan/naproxen) PO at migraine onset; may repeat after 2 hours if needed; maximum 2 tablets per 24 hours
	\| preparations = 85 mg sumatriptan / 500 mg naproxen sodium tablets; lower-dose 10/60 mg pediatric (Treximet pediatric)		\| preparations = 85 mg sumatriptan / 500 mg naproxen sodium tablets; lower-dose 10/60 mg pediatric (Treximet pediatric)
	\| fda_max = 2 tablets per 24 hours; ≤4 days per month to avoid ~~medication~~-overuse headache		\| fda_max = 2 tablets per 24 hours; ≤4 days per month to avoid medicine-overuse headache
	\| pill_id =		\| pill_id =
	\| routes = Oral		\| routes = Oral

MDElliottMD: parser-claude batch MedTemplate pre-fill, mind-medicine combination

2026-05-23T04:44:11Z

parser-claude batch MedTemplate pre-fill, mind-medicine combination

New page

{{MedTemplate
| generic = Sumatriptan / Naproxen
| brand = Treximet
| structure =
| classes = [[:Category:Triptans|Triptan (5-HT1B/1D agonist)]], [[:Category:NSAIDs|NSAID (naproxen)]], [[:Category:Antimigraine_agents|Antimigraine agent]], [[:Category:Fixed-dose_combinations|Fixed-dose combination]]
| uses = <vote slug="acute-migraine-use">Acute migraine treatment (with or without aura)</vote>
| starting_dose = 1 tablet (85/500 mg sumatriptan/naproxen) PO at migraine onset; may repeat after 2 hours if needed; maximum 2 tablets per 24 hours
| preparations = 85 mg sumatriptan / 500 mg naproxen sodium tablets; lower-dose 10/60 mg pediatric (Treximet pediatric)
| fda_max = 2 tablets per 24 hours; ≤4 days per month to avoid medication-overuse headache
| pill_id =
| routes = Oral
| onset = Headache relief at 30-60 minutes
| duration = 4-8 hours
| halflife = Sumatriptan ~2.5 hours; naproxen 12-15 hours<ref name="treximet-label">FDA Prescribing Information, Treximet (sumatriptan / naproxen sodium), Currax Pharmaceuticals, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021926s022lbl.pdf</ref>
| bioavailability = Sumatriptan ~15% (oral; substantial first-pass); naproxen ~95%<ref name="treximet-label" />
| pregnancy = Avoid; NSAID-class restriction after 20 weeks (FDA 2020) and limited triptan pregnancy data.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US. NSAID-class '''Boxed Warning''' for CV thrombotic events and GI bleeding; triptans contraindicated in coronary artery disease, peripheral vascular disease, uncontrolled hypertension, and recent ergot or MAOI use<ref name="treximet-label" />
| mechanism = <vote slug="treximet-mech-claim">Sumatriptan is a selective 5-HT1B and 5-HT1D receptor agonist that vasoconstricts intracranial arteries and inhibits trigeminal nerve transmission, reversing the neurovascular mechanism of migraine. Naproxen is a non-selective NSAID providing anti-inflammatory adjuvant effect; the combination outperforms either agent alone in randomized trials (faster onset, longer-lasting relief, lower 24-hour recurrence).</vote> The dual-mechanism design exploits the inflammatory component of migraine that triptan monotherapy does not fully address. Risk of serotonin syndrome with SSRIs/SNRIs is theoretical but generally not seen clinically at triptan doses<ref name="treximet-label" />.
}}

== References ==
<references />